Clinical trials: Eczema/Atopic Dermatitis
Psoriasis, Atopic Dermatitis
Novel Skin Barrier Product Versus Petrolatum for Skin Barrier Dysfunction
The goal of this clinical trial is to learn if a novel barrier topical product works to treat barrier dysfunction in adults. It will also learn about the safety of the novel barrier topical product.
- Conditions
- Psoriasis, Atopic Dermatitis, Xerosis, Contact Dermatitis
- Trial name
- NCT07183423
- Testing
- Novel barrier repair topical product, Petrolatum
- Where
- Philippines
- Volunteers
- 26 people
- Sponsor
- Makati Medical Center
Dermatitis Atopic
Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)
Primary Objective: To explore associations between biomarkers of atopic dermatitis (AD) and: Disease state and time course of AD, Disease state and evolution of selected atopic comorbid conditions, Effectiveness of specific AD…
- Trial name
- NCT03849716
- Testing
- Blood sample, Cheek swab
- Where
- 48 sites in United States, Argentina and 7 more
- Volunteers
- 266 people
- Sponsor
- Sanofi
Atopic Dermatitis, Healthy
Assessment of Clinical, Biological and Biometrological Parameters in Adults Subjects With Atopic Dermatitis
In most recent years, the gut microbiome has been highlighted as a key player in the control of organs distant from the gut. Indeed, studies have raised evidence that gut microbiota exerts a control on various diseases including…
- Trial name
- NCT07017348
- Testing
- Clinical assessments, Biometrological measurements, Biological sampling
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Dermo Cosmetique
Dermatitis, Atopic
Tacrolimus Ointment Long Term Safety in Young Children With Atopic Dermatitis
The objective of this study is to assess the safety and efficacy of 0.03% tacrolimus ointment as long-term treatment in paediatric patients with atopic dermatitis.
- Trial name
- NCT00560326
- Testing
- Tacrolimus Ointment 0.03%
- Where
- 8 sites in Canada, Finland and 3 more
- Volunteers
- 50 people
- Sponsor
- Astellas Pharma Inc
Atopic Dermatitis
Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)
Primary objective: To evaluate the efficacy of tralokinumab compared with placebo in treating moderate to severe atopic dermatitis (AD).
- Trial name
- ECZTRA 1 (NCT03131648)
- Testing
- Tralokinumab
- Where
- 123 sites in United States, France and 3 more
- Volunteers
- 802 people
- Sponsor
- LEO Pharma
Atopic Dermatitis, Eczema
Evaluating the Effect of Bathing Additives in Atopic Dermatitis
This proposed project will be an open-label, split-arm, randomized controlled pilot study. Up to 60 patients diagnosed with atopic dermatitis (eczema) will be enrolled in the study.
- Trial name
- NCT04001855
- Testing
- Dilute vinegar (acetic acid), Dilute bleach
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Arizona
Atopic Dermatitis Eczema
Cosmetic Study to Improve the Appearance of Skin Afflicted With Mild to Moderate Atopic Dermatitis.
The purpose of this study is to observe the performance of a cosmetic product, AO+Mist, on the appearance of arm skin in subjects with atopic dermatitis
- Trial name
- NCT03268174
- Testing
- AO+Mist
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- AOBiome LLC
Atopic Dermatitis
A Study to Evaluate the Efficacy and Safety of LNK01004 Ointment in Adults With Atopic Dermatitis
This study will evaluate the efficacy and safety of two concentrations (0.3 percent [%] and 1%) of twice daily LNK01004 ointment for the topical treatment in adult subjects with atopic dermatitis.
- Trial name
- NCT07071610
- Testing
- LNK01004 ointment 0.3%, LNK01004 ointment 1.0%, Vehicle
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Lynk Pharmaceuticals Co., Ltd
Atopic Dermatitis
Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Pilot
A new flu vaccine which is injected into the skin instead of into the muscle has recently been approved by the Food and Drug Administration for vaccination of the general population including patients with atopic dermatitis (AD).
- Trial name
- NCT01518478
- Testing
- Fluzone® Intradermal (Sanofi Pasteur Inc.)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dermatitis, Atopic
A Study of an Eczema Spot Treatment in Providing Eczema Symptoms Relief and Lasting Itch Relief to Affected Skin Area
The purpose of this study is to evaluate the efficacy (assessed by clinical evaluation of eczema/atopic lesion severity [atopic dermatitis severity index {ADSI} scoring] and perceived benefits in itch [visual analog score {VAS}…
- Trial name
- NCT05226143
- Testing
- Gel Cream
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Atopic Dermatitis, Skin Diseases
BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort
Atopic dermatitis (eczema) is a complicated skin condition. In fact, it represents many different underlying problems. These include abnormalities in the skin barrier, the immune system and the ability to handle different…
- Conditions
- Atopic Dermatitis, Skin Diseases, Eczema
- Trial name
- BRONTE (NCT04818138)
- Testing
- Narrowband UVB phototherapy, Broadband UVB phototherapy
- Where
- Canada
- Volunteers
- 69 people
- Sponsor
- Women's College Hospital
Moderate-to-severe Atopic Dermatitis
A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis
The goal of this clinical trial is to evaluate the efficacy and safety of JYP0061 in adult patients with moderate-to-severe atopic dermatitis.
- Trial name
- NCT06158490
- Testing
- JYP0061 15 mg, JYP0061 30 mg
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Guangzhou JOYO Pharma Co., Ltd
Atopic Dermatitis
A Study to Assess the Efficacy and Safety of PG-011 Gel in Adolescents and Adults With Atopic Dermatitis
This is a Multicenter, Randomized, Double-blind, Placebo-controlled seamless and adaptive-designed phase IIb/III study to Assess the Efficacy and Safety of topical use of PG-011 Gel in adolescents and Adults With Atopic…
- Trial name
- NCT06587685
- Testing
- PG-011Gel, Vehicle
- Where
- China
- Volunteers
- 472 people
- Sponsor
- Prime Gene Therapeutics Co., Ltd.
Atopic Dermatitis
A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis
This is a randomized double-blind, placebo-controlled, multicenter phase III clinical study evaluating the efficacy and safety of AK120 in the treatment of moderate-to-severe AD in adolescents.
- Trial name
- NCT06767540
- Where
- 28 sites in China
- Volunteers
- 198 people
- Sponsor
- Akeso
Atopic Eczema
A Study to Evaluate Adex Gel in the Treatment of Atopic Eczema.
This is a prospective, open label, uncontrolled study which will be performed in multiple Primary Care (GP) centres, in approximately 60 children (aged 1 year to 15 years) who have moderate atopic eczema and who are not currently…
- Trial name
- NCT05454722
- Testing
- ADEX Gel
- Where
- 2 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Dermal Laboratories Ltd
Dermatitis, Atopic
Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to severe atopic dermatitis and have completed a qualifying parent study.
- Trial name
- JADE EXTEND (NCT03422822)
- Testing
- Abrocitinib 100 mg, Abrocitinib 200 mg
- Where
- 539 sites in United States, Argentina and 26 more
- Volunteers
- 3,166 people
- Sponsor
- Pfizer
Atopic Dermatitis
Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis
This is a Phase 2 open label study of ATI-2138 in participants with moderate to severe atopic dermatitis.
- Trial name
- NCT06585202
- Testing
- ATI-2138
- Where
- 6 sites in United States
- Volunteers
- 14 people
- Sponsor
- Aclaris Therapeutics, Inc.
Atopic Dermatitis
Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis.
The purpose of this study is to determine whether QAW039 is safe and has beneficial effects in people who have moderate to severe atopic dermatitis (AD).
- Trial name
- NCT01785602
- Testing
- QAW039
- Where
- 18 sites in Australia, Austria and 6 more
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT06947993
- Testing
- GHZ339
- Where
- 105 sites in United States, Argentina and 15 more
- Volunteers
- 224 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
Multicenter, randomized, double-blind, placebo-controlled, parallel arm clinical study designed to evaluate the efficacy and safety of eblasakimab in participants with moderate-to-severe atopic dermatitis (AD) previously treated…
- Trial name
- NCT05694884
- Testing
- ASLAN004
- Where
- 27 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- ASLAN Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.